



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

**Meeting to commence at 9.30 am on Wednesday 9th February
2022
(via Zoom)**

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of the previous meeting** 1/AWMSG/0222
5. **Chairman's report**
6. **Primary care antimicrobial guidelines** 2/AWMSG/0222
7. **CEPP national audit – focus on antibiotic prescribing** 3/AWMSG/0222
8. **Management of Clostridioides difficile infection in Wales** 4/AWMSG/0222
9. **Management of recurrent symptomatic UTI in adult women** 5/AWMSG/0222
10. **All Wales advice on oral anticoagulation in non-valvular atrial fibrillation (2021/22 update)** 6/AWMSG/0222
11. **NPIs 2022-23 Supporting information for prescribers and healthcare professionals** 7/AWMSG/0222
12. **Feedback from AWPAG meeting held 1st December 2021** 8/AWMSG/0222
13. **Appraisal 1 – Full Submission** 9/AWMSG/0222
Tirbanibulin (Klisyri®) for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults Appendices
14. **Appraisal 2 – Limited Submission** 10/AWMSG/0222
Clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) for symptomatic treatment of focal spasticity of upper limbs in paediatric cerebral palsy patients, two years of age or older Appendices

To protect commercial confidentiality the following appraisals will be held in private and all observers will be asked to leave the meeting

15. **Appraisal 3 – Paediatric Licence Extension (PAS)** 11/AWMSG/0222
Ravulizumab (Ultomiris®) for the treatment of paediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal haemoglobinuria (PNH):
- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.
- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months
Appendices
16. **Appraisal 4 – Full Submission (WPAS)** 12/AWMSG/0222
Inclisiran (Leqvio®) in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL C goals with the maximum tolerated dose of a statin, or; alone or in combination with other lipid lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated.
Appendices
17. **Appraisal 5 – Full Submission (WPAS)** 13/AWMSG/0222
Buprenorphine (Sixmo®) substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment
Appendices

The outcome of all appraisals will be uploaded to the AWMSG website after the meeting.

Date and time of next meeting: Tuesday 8th March 2022 at 9:30 am